Expert Financial Analysis and Reporting

Today’s issue of the Wall Street Journal carries an opinion piece entitled “The Treatment That Could Crush Covid”. The article hypothesizes that living cells which the author calls medicinal signaling cells promise to be an effective treatment for Adult Respiratory Distress Syndrome (ARDS). ARDS is a condition that results from an overreaction of the immune […]

Investment Opportunity One of the areas that I want to focus my investment research on is CAR-T therapy. I believe that this is one of the most significant opportunities for new drug development over the coming decades and will produce some outstanding investment opportunities. The first two CAR-T drugs, Novartis’ Kymriah and Gilead’s Yescarta, were […]

Recent Price Strength and Investment View The long term fundamentals of Cryoport are so strong that I anticipate I will be recommending the stock consistently for the next several years. It is uniquely positioned to support the overwhelming majority of cell based therapies that require temperature controlled shipping, particularly cryogenic. It is positioned to benefit […]

Fourth Quarter Biopharma Results Come Up Short Cryoport pre-announced 4Q, 2019 results on Friday January 10, 2020; audited full year results will be released on March 5, 2020. Management stated that it expects to report 2019 revenues of about $33.9 million (an increase of 73%) and 4Q, 2019 revenues of around $9.2 million (up 61% […]

Investment Overview ASH is a Key Annual Event The annual meeting of the American Society of Hematology (ASH) is a closely watched showcase for new clinical data on drugs. Each year, there are literally thousands of papers presented. One of the really hot areas this year (as has been the case for the last two […]

Investment Perspective The main revenue driver for Cryoport from 2015 to 2019 came from providing cryogenic shipping services to companies conducting clinical trials preparatory to seeking regulatory approval. However, this began to change in 1Q, 2018 as regulatory approvals were gained for two commercial products, the CAR-T drugs Kymriah and Yescarta. These were supported by […]

Opinion on Stock The recent sharp price decline has not been attributable to any change in perceived or actual fundamentals of Cryoport. (See the appendix of this report for a discussion on price behavior over the last month.) I have stated repeatedly that Cryoport has one of the best business models that I have seen […]

Cryoport reported a very strong quarter as sales increased by 83%. The key biopharma segment increased sales by 81%. This was led by a 326% increase in sales stemming from support of the commercial CAR-T products, Kymriah and Yescarta. Some $600,000 of incremental sales were recorded from the acquisition of Cryogene which closed on May […]

Cryoport will report 2Q, 2019 results on August 8, 2019 at 5:00 PM EST. One area of keen interest for investors will be sales relating to the support of the CAR-T products-Gilead’s Yescarta and Novartis’ Kymriah. Gilead has reported that Yescarta sales in 2Q, 2019 were $120 million which compares to my last published estimate […]

Overview of Equity Offering Cryoport quickly and very successfully executed an equity offering after the close on June 19, 2019. It sold 3,750,000 shares at a price to investors of $17.00 per share. This was at a discount of about 9% from the closing price of $18.62. After underwriting discounts, Cryoport received $59.80 million which […]